Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comAugmentation of Venlafaxine with Bupropion: Risks Associated with a Triple Monoamine Reuptake Inhibition Approach to Partially Responsive Depression

Bupropion inhibits cytochrome P450 2D6,5 which is the enzyme that converts venlafaxine into an active metabolite, desvenlafaxine. When CYP2D6 is inhibited, venlafaxine levels rise at the expense of desvenlafaxine. Because the renal excretion of venlafaxine is small, the consequence is increased dose-dependent venlafaxine-related adverse effects.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form